Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models
about
Pancreatic β Cell Mass DeathRenal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: Clinical data and mechanism of actionSodium-glucose cotransporter 2 inhibition: cardioprotection by treating diabetes-a translational viewpoint explaining its potential salutary effectsThe role of kidney in glucose homeostasis--SGLT2 inhibitors, a new approach in diabetes treatment.Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studiesCanagliflozin-current status in the treatment of type 2 diabetes mellitus with focus on clinical trial data.Effects of canagliflozin on weight loss in high-fat diet-induced obese mice.Pharmacokinetic and pharmacodynamic profiles of canagliflozin in Japanese patients with type 2 diabetes mellitus and moderate renal impairment.Serum uric acid and disorders of glucose metabolism: the role of glycosuriaEmpagliflozin in the treatment of type 2 diabetes: evidence to dateEfficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise.Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trialCanagliflozin: effects in overweight and obese subjects without diabetes mellitus.Ipragliflozin: A novel sodium-glucose cotransporter 2 inhibitor developed in Japan.Beneficial effects of canagliflozin in combination with pioglitazone on insulin sensitivity in rodent models of obese type 2 diabetes.A mathematical model of rat proximal tubule and loop of Henle.Absence of Drug-Drug Interactions Between Luseogliflozin, a Sodium-Glucose Co-transporter-2 Inhibitor, and Various Oral Antidiabetic Drugs in Healthy Japanese Males.Modeling oxygen consumption in the proximal tubule: effects of NHE and SGLT2 inhibitionSodium-Glucose Linked Transporter 2 (SGLT2) Inhibitors in the Management Of Type-2 Diabetes: A Drug Class Overview.Functional expression of sodium-glucose transporters in cancer.A validated LC-MS/MS method for the determination of canagliflozin, a sodium-glucose co-transporter 2 (SGLT-2) inhibitor, in a lower volume of rat plasma: application to pharmacokinetic studies in rats.Sodium-Glucose Cotransporter 2 Inhibitor and a Low Carbohydrate Diet Affect Gluconeogenesis and Glycogen Content Differently in the Kidney and the Liver of Non-Diabetic MiceSGLT inhibitors attenuate NO-dependent vascular relaxation in the pulmonary artery but not in the coronary artery.SGLT2 inhibitors - an insulin-independent therapeutic approach for treatment of type 2 diabetes: focus on canagliflozin.SGLT2 inhibitor therapy improves blood glucose but does not prevent diabetic bone disease in diabetic DBA/2J male mice.Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin.SHR3824, a novel selective inhibitor of renal sodium glucose cotransporter 2, exhibits antidiabetic efficacy in rodent models.Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease.Validation of a novel method for determining the renal threshold for glucose excretion in untreated and canagliflozin-treated subjects with type 2 diabetes mellitus.Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study.Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trialTofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db/db mice.Tofogliflozin, a sodium/glucose cotransporter 2 inhibitor, attenuates body weight gain and fat accumulation in diabetic and obese animal models.A review of clinical efficacy and safety of canagliflozin 300 mg in the management of patients with type 2 diabetes mellitus.Safe and pragmatic use of sodium-glucose co-transporter 2 inhibitors in type 2 diabetes mellitus: South Asian Federation of Endocrine Societies consensus statement.The renal effects of SGLT2 inhibitors and a mini-review of the literature.Canagliflozin: A Novel SGLT2 Inhibitor for Type 2 Diabetes Mellitus.Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes.Inhibition of the sodium glucose co-transporter-2: its beneficial action and potential combination therapy for type 2 diabetes mellitus.Differentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus.
P2860
Q26752571-77C2B6C0-90B1-4078-B732-DB6E42BF2635Q27027105-56F01CFB-A8A5-4630-BF18-676B3FFE27C4Q28072765-BC5DFBA6-0AD5-4404-9794-FA8A5891391FQ30663494-AFBF1C5D-B129-46ED-A90D-F26B7FF53887Q33613143-91D00519-1755-451C-B388-FC9BCFE76D5CQ33759610-AEECA1CB-4658-446B-BC34-D20A90E849E6Q33860008-E107C329-2899-4AB6-AD5B-C7AA1462D30CQ34208581-5EF8FFBC-C6D0-48E4-9157-E077722BE1ECQ34272447-D1F6A217-86F1-41E1-AB2F-4FC420E0DD41Q34502358-F7D4D62E-EF0D-4A7F-BEB4-54D1FA8E887CQ34646948-27538E8F-1355-4D7B-A435-332EF1677390Q34804900-4B03DED3-D9D0-48AB-B04B-E9A258862527Q34851219-5CBFAE39-21B3-4675-A35C-ABC8EFC5975EQ35049845-AD489EE4-429B-4D8C-9048-010878D04FA9Q35548033-2E92E1E8-043F-4F61-B8E5-EF8C6AB416CBQ35622466-586127F6-759F-4B66-AEE5-02B36A09C1F8Q35666237-D52D16CD-948F-4147-92EF-0FAB66BDF5A1Q35749639-F42552E4-20D3-440D-8F89-4F7AFB11767AQ35831426-B01C5F0F-CBDD-4D02-995C-575B457C0341Q35909986-79A1208A-716C-4D24-ABC2-1E700BC5626BQ35962105-512B4329-DE74-4C52-B0AB-CD78F9126314Q36057947-DB6B2388-CC2F-41BC-B324-5C310E15FD4BQ36237217-EE36C7EE-96D1-47F8-8805-BDD91DAEB42AQ36277977-CCFC7CB5-7A1C-4D48-9B25-FCEB6D03584CQ36372598-99D1771E-4A14-49D5-BCE9-78785053CE04Q36431654-BF1B2441-B1F8-462A-87DB-AD53491483C6Q36745809-7B65B1CE-0E8B-49C3-BFD8-5FA1A7D11C17Q36845771-26ED0561-2970-4D8F-9349-B7793BF11F1EQ36997767-4F2BCB4F-7A94-433B-BD95-DE79E7B62AF4Q37022726-3492F297-A5D1-4B56-B136-F339CB11F1BEQ37106527-4669F3CB-95F0-403F-BB83-DD0247182647Q37219076-BA6061E5-7F46-4879-93B6-8676234C35A0Q37536310-221AAA01-1650-4335-96F7-B22BDB52CE4CQ37588842-2823B301-A148-46D7-B676-74813F989374Q37588847-B2564B75-AC3F-4178-B344-EAEAC5C1F38FQ37632127-EC64DCBB-D183-434C-B478-EFE8EB6C32E9Q37690751-0A1CFE94-A523-495B-BB4D-B1D6B96F8651Q37692849-17F8EB83-6DC4-4AB7-8CA2-35E854ACA8F6Q38075117-CD0A1F00-1A5F-44AC-A9AD-A9C86671330EQ38085691-7008BCB3-4F8F-472E-A6B4-C14893363622
P2860
Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models
description
2012 nî lūn-bûn
@nan
2012 թուականին հրատարակուած գիտական յօդուած
@hyw
2012 թվականին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Effect of canagliflozin on ren ...... mal and diabetic animal models
@ast
Effect of canagliflozin on ren ...... mal and diabetic animal models
@en
Effect of canagliflozin on ren ...... mal and diabetic animal models
@nl
type
label
Effect of canagliflozin on ren ...... mal and diabetic animal models
@ast
Effect of canagliflozin on ren ...... mal and diabetic animal models
@en
Effect of canagliflozin on ren ...... mal and diabetic animal models
@nl
prefLabel
Effect of canagliflozin on ren ...... mal and diabetic animal models
@ast
Effect of canagliflozin on ren ...... mal and diabetic animal models
@en
Effect of canagliflozin on ren ...... mal and diabetic animal models
@nl
P2093
P2860
P921
P3181
P1433
P1476
Effect of canagliflozin on ren ...... mal and diabetic animal models
@en
P2093
Bruce Conway
Chiaki Kuriyama
David Polidori
Jamie Conway
Keith Demarest
Kenji Arakawa
Kiichiro Ueta
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0030555
P407
P577
2012-01-01T00:00:00Z